Literature DB >> 32991949

Reality CHEK: Understanding the biology and clinical potential of CHK1.

Fiifi Neizer-Ashun1, Resham Bhattacharya2.   

Abstract

The DNA damage response enables cells to cope with various stresses that threaten genomic integrity. A critical component of this response is the serine/threonine kinase CHK1 which is encoded by the CHEK1 gene. Originally identified as a regulator of the G2/M checkpoint, CHK1 has since been shown to play important roles in DNA replication, mitotic progression, DNA repair, and overall cell cycle regulation. However, the potential of CHK1 as a cancer therapy has not been realized clinically. Herein we expound our current understanding of the principal roles of CHK1 and highlight different avenues for CHK1 targeting in cancer therapy.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CHK1; Cell cycle; DNA Damage response

Year:  2020        PMID: 32991949     DOI: 10.1016/j.canlet.2020.09.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  Ganoderma lucidum enhances carboplatin chemotherapy effect by inhibiting the DNA damage response pathway and stemness.

Authors:  Ivette J Suárez-Arroyo; Ariana Acevedo-Díaz; Tiffany J Ríos-Fuller; Gabriela Ortiz-Soto; Ricardo Vallejo-Calzada; Jael Reyes-Chea; Gerónimo Maldonado-Martínez; Robert J Schneider; Michelle M Martínez-Montemayor
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

2.  Chk1 inhibitor-induced DNA damage increases BFL1 and decreases BIM but does not protect human cancer cell lines from Chk1 inhibitor-induced apoptosis.

Authors:  Andrew J Massey
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

3.  Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer.

Authors:  Sadanori Watanabe; Akitada Yogo; Tsuguteru Otsubo; Hiroki Umehara; Jun Oishi; Toru Kodo; Toshihiko Masui; Shigeo Takaishi; Hiroshi Seno; Shinji Uemoto; Etsuro Hatano
Journal:  BMC Cancer       Date:  2022-05-03       Impact factor: 4.638

4.  Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.

Authors:  Jason Ostergaard; Leslie M Jonart; Maryam Ebadi; Stacia L Koppenhafer; David J Gordon; Peter M Gordon
Journal:  Br J Haematol       Date:  2021-06-07       Impact factor: 6.998

Review 5.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.

Authors:  Lenka Stolarova; Petra Kleiblova; Marketa Janatova; Jana Soukupova; Petra Zemankova; Libor Macurek; Zdenek Kleibl
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

Review 6.  Mitotic and DNA Damage Response Proteins: Maintaining the Genome Stability and Working for the Common Good.

Authors:  Fernando Luna-Maldonado; Marco A Andonegui-Elguera; José Díaz-Chávez; Luis A Herrera
Journal:  Front Cell Dev Biol       Date:  2021-12-13

Review 7.  O-GlcNAcylation links oncogenic signals and cancer epigenetics.

Authors:  Lidong Sun; Suli Lv; Tanjing Song
Journal:  Discov Oncol       Date:  2021-11-24

Review 8.  BET Proteins as Attractive Targets for Cancer Therapeutics.

Authors:  Joanna Sarnik; Tomasz Popławski; Paulina Tokarz
Journal:  Int J Mol Sci       Date:  2021-10-14       Impact factor: 5.923

Review 9.  The Role of Hsp27 in Chemotherapy Resistance.

Authors:  Marios Lampros; Nikolaos Vlachos; Spyridon Voulgaris; George A Alexiou
Journal:  Biomedicines       Date:  2022-04-14

Review 10.  DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.

Authors:  Ruixue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.